Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar;5(2):203-13.
doi: 10.1111/j.1751-7915.2011.00278.x. Epub 2011 Sep 6.

J-LEAPS Peptide and LEAPS Dendritic Cell Vaccines

Affiliations
Free PMC article
Review

J-LEAPS Peptide and LEAPS Dendritic Cell Vaccines

Ken S Rosenthal et al. Microb Biotechnol. .
Free PMC article

Abstract

The J-LEAPS vaccines contain a peptide from β-2-microglobulin covalently attached to disease-related peptides of 8-30 amino acids which contain a T cell epitope. The J-LEAPS vaccines can initiate a protective Th1 immune response or modulate an ongoing Th17 autoimmune response to the peptide. J-LEAPS vaccines activate and direct the nature of the subsequent immune response by promoting the maturation of precursor cells into a unique type of dendritic cell that produces interleukin 12, but not IL-1 or tumour necrosis factor, and presents the antigenic peptide to T cells. Adoptive transfer of JgD-LEAPS dendritic cells, matured with an anti-HSV-1 vaccine, promoted antigen-specific Th1 protection against lethal challenge with the virus. J-LEAPS peptide immunogens and J-LEAPS dendritic cell vaccines have potential applications for antimicrobial prevention and therapy, treatment of autoimmune diseases, and for cancer immunotherapy.

Figures

Figure 1
Figure 1
Models for J‐LEAPS vaccine initiation of Th1 immune responses and modulation of ongoing autoimmunity. J‐LEAPS vaccines induce the differentiation of precursors into IL‐12‐producing DCs that are capable of promoting Th1‐related cytokines (IL‐2, IFNγ) production from naïve T cells and as an antigen‐specific boost in response. DCs generated by CEL‐2000 (J‐coll) modulate the ongoing Th17 autoimmune response in rheumatoid arthritic mice to block the progression of autoimmune disease.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Allen T.M., Altfeld M., Geer S.C., Kalife E.T., Moore C., O'Sullivan K.M. Selective escape from CD8− T‐cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV‐1) sequence diversity and reveals constraints on HIV‐1 evolution. J Virol. 2005;79:13239–13249. et al. - PMC - PubMed
    1. Banchereau J., Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. - PubMed
    1. Banks T.A., Allen E.M., Dasgupta S., Sandri‐Golden R., Rouse B.T. HSV‐1 specific cytotoxic T lymphocytes recognize immediate early protein ICP27. J Virol. 1991;65:3185–3191. - PMC - PubMed
    1. Banks T.A., Nair S., Rouse B.T. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate‐early protein ICP27 of herpes simplex virus. J Virol. 1993;37:613–616. - PMC - PubMed
    1. Borges L., Hsu M., Fanger N., Kubin M., Cosman D. A family of human lymphoid and myeloid Ig‐like receptors, some of which bind to MHC class I molecules. J Immunol. 1997;159:5192–5196. - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback